Cargando…

Polymeric Carriers for Delivery of RNA Cancer Therapeutics

As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirón-Barroso, Sofía, Correia, Joana S., Frampton, Adam E., Lythgoe, Mark P., Clark, James, Tookman, Laura, Ottaviani, Silvia, Castellano, Leandro, Porter, Alexandra E., Georgiou, Theoni K., Krell, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412371/
https://www.ncbi.nlm.nih.gov/pubmed/36005826
http://dx.doi.org/10.3390/ncrna8040058
_version_ 1784775477653667840
author Mirón-Barroso, Sofía
Correia, Joana S.
Frampton, Adam E.
Lythgoe, Mark P.
Clark, James
Tookman, Laura
Ottaviani, Silvia
Castellano, Leandro
Porter, Alexandra E.
Georgiou, Theoni K.
Krell, Jonathan
author_facet Mirón-Barroso, Sofía
Correia, Joana S.
Frampton, Adam E.
Lythgoe, Mark P.
Clark, James
Tookman, Laura
Ottaviani, Silvia
Castellano, Leandro
Porter, Alexandra E.
Georgiou, Theoni K.
Krell, Jonathan
author_sort Mirón-Barroso, Sofía
collection PubMed
description As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘druggable’ active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic.
format Online
Article
Text
id pubmed-9412371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94123712022-08-27 Polymeric Carriers for Delivery of RNA Cancer Therapeutics Mirón-Barroso, Sofía Correia, Joana S. Frampton, Adam E. Lythgoe, Mark P. Clark, James Tookman, Laura Ottaviani, Silvia Castellano, Leandro Porter, Alexandra E. Georgiou, Theoni K. Krell, Jonathan Noncoding RNA Review As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘druggable’ active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic. MDPI 2022-08-02 /pmc/articles/PMC9412371/ /pubmed/36005826 http://dx.doi.org/10.3390/ncrna8040058 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mirón-Barroso, Sofía
Correia, Joana S.
Frampton, Adam E.
Lythgoe, Mark P.
Clark, James
Tookman, Laura
Ottaviani, Silvia
Castellano, Leandro
Porter, Alexandra E.
Georgiou, Theoni K.
Krell, Jonathan
Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title_full Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title_fullStr Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title_full_unstemmed Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title_short Polymeric Carriers for Delivery of RNA Cancer Therapeutics
title_sort polymeric carriers for delivery of rna cancer therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412371/
https://www.ncbi.nlm.nih.gov/pubmed/36005826
http://dx.doi.org/10.3390/ncrna8040058
work_keys_str_mv AT mironbarrososofia polymericcarriersfordeliveryofrnacancertherapeutics
AT correiajoanas polymericcarriersfordeliveryofrnacancertherapeutics
AT framptonadame polymericcarriersfordeliveryofrnacancertherapeutics
AT lythgoemarkp polymericcarriersfordeliveryofrnacancertherapeutics
AT clarkjames polymericcarriersfordeliveryofrnacancertherapeutics
AT tookmanlaura polymericcarriersfordeliveryofrnacancertherapeutics
AT ottavianisilvia polymericcarriersfordeliveryofrnacancertherapeutics
AT castellanoleandro polymericcarriersfordeliveryofrnacancertherapeutics
AT porteralexandrae polymericcarriersfordeliveryofrnacancertherapeutics
AT georgioutheonik polymericcarriersfordeliveryofrnacancertherapeutics
AT krelljonathan polymericcarriersfordeliveryofrnacancertherapeutics